- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00578214
Safety and Efficacy of Oral Midazolam for Perioperative Anxiety Relief of Patients Undergoing Mohs Micrographic Surgery
Randomized Controlled and Prospective Studies of Safety and Efficacy of Oral Midazolam for Perioperative Anxiolysis of Patients Undergoing Mohs Micrographic Surgery.
Midazolam is an approved sedative medication used for medical procedures. This study was being done to document the safety and efficacy of midazolam in improving anxiety, heart rate, and blood pressure in patients prior to undergoing Mohs micrographic surgery for the treatment of skin cancer (basal cell carcinoma or squamous cell carcinoma). Midazolam may make a patient relaxed and sleepy, and lower blood pressure. These effects last for about 2 hours.
This study had two parts. In the first part, eligible patients were randomized to either receiving one standard dose of midazolam syrup or placebo syrup before their surgery, with neither the patient nor the study team knowing which patient received the study drug. In the second part, patients who were not eligible to participate in the randomized study or who refused to participate in the randomized study were enrolled in a prospective arm where they knew they were receiving midazolam syrup. In the prospective arm, the doses were based on the patient's weight, and patients were given additional doses of midazolam syrup as necessary to control their anxiety.
The primary hypothesis of this study was that a single dose of oral midazolam syrup to patients prior undergoing outpatient Mohs micrographic surgery for skin cancer would result in lower anxiety scores at 60 minutes compared to placebo. In addition, the second hypothesis of this study was that patients given oral midazolam would have the rate of adverse events that was not worse than 25% higher than in the placebo group.
Study Overview
Status
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 1 or 2 sites of biopsy-confirmed squamous cell or basal cell carcinomas limited to head and neck regions
Inclusion Criteria for Prospective Arm:
- Patients wishing to receive oral midazolam in a non-blinded fashion will not be excluded based on the size of an individual tumor, total number of tumors, or prior history of oral midazolam
- No upper weight limitation
Exclusion Criteria:
- Prior history of allergy to midazolam or any of the syrup components
- History of hypersensitivity to other benzodiazepines
- Congestive heart failure (AHA Class III and IV)
- Renal failure requiring hemodialysis
- End-stage liver failure
- Chronic alcoholism or alcohol intoxication within 24 hours of surgery
- Untreated or uncontrolled open angle glaucoma
- Uncontrolled hypertension
- History of psychoses or affective disorders
- Neuromuscular disorders such as myasthenia gravis
- Chronic obstructive pulmonary disease
- Patients on medications interfering with renal excretion or microsomal metabolism unless the last dose was taken greater than or equal to 5 half-lives prior to surgery
- Patients weighing less than 100 lb (45 kg)
- Pregnant women; women of childbearing potential will be required to take an in-office urine pregnancy test.
- Breast-feeding mothers must stop breast-feeding for 7 days after taking midazolam to take part in this study
Additional Exclusion Criteria for Randomized Arms:
- Patients with a single cancer > 5 cm in the greatest dimension or with more than 2 cancers
- Patients who were previously premedicated with oral midazolam during prior Mohs micrographic surgery episodes
- Patients weighing more than 220 lb (100 kg)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
Lidocaine 1% with 1:100,000 epinephrine
The placebo was prepared as a color- and texture-matched cherry flavored syrup without midazolam.
|
Active Comparator: Randomized Midazolam
Single-dose midazolam
|
Midazolam was prepared in a 2 mg/ml cherry flavored syrup.
In the randomized arm, patients received a single-dose administration of 5 ml (10 mg) of the midazolam syrup.
Other Names:
Lidocaine 1% with 1:100,000 epinephrine
|
Experimental: Prospective Midazolam
|
Lidocaine 1% with 1:100,000 epinephrine
Midazolam was prepared in a 2 mg/ml cherry flavored syrup.
Dosing in the prospective arm was based on weight (>45 to 77 kg, 10 mg; >77 to 100 kg, 15 mg; greater than or equal to 100 kg, 20 mg).
In the prospective arm patients were given additional doses of midazolam as necessary (in 5 mg increments) to achieve and maintain the desired level of anxiolysis.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Patient Anxiety at Baseline
Time Frame: Baseline (prior to drug administration)
|
A 10-point visual analog scale (VAS) was used to measure anxiety.
The patients marked on the scale their feeling of anxiety.
The lowest value possible was 0 (no anxiety) and the highest value possible was 10 (highest possible anxiety).
|
Baseline (prior to drug administration)
|
Patient Anxiety at 60 and 120 Minutes
Time Frame: 60 and 120 minutes after drug administration
|
A 10-point visual analog scale (VAS) was used to measure anxiety.
The patients marked on the scale their feeling of anxiety.
The lowest value possible was 0 (no anxiety) and the highest value possible was 10 (highest possible anxiety).
|
60 and 120 minutes after drug administration
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Patient Alertness at Baseline
Time Frame: Baseline (prior to drug administration)
|
A 10-point visual analog scale (VAS) was used to measure alertness.
The patients marked on the scale their feeling of alertness.
The lowest value possible was 0 (awake) and the highest value possible was 10 (barely awake).
|
Baseline (prior to drug administration)
|
Patient Alertness at 60 and 120 Minutes
Time Frame: 60 and 120 minutes after drug administration
|
A 10-point visual analog scale (VAS) was used to measure alertness.
The patients marked on the scale their feeling of alertness.
The lowest value possible was 0 (awake) and the highest value possible was 10 (barely awake).
|
60 and 120 minutes after drug administration
|
Patient Cognitive Function at Baseline and 60 Minutes
Time Frame: baseline (prior to drug administration) and 60 minutes after drug administration
|
Cognitive function was measured by the Mini-Mental State Examination (MMSE), a brief 30 point questionnaire test.
The scores can range from 0 (low cognitive function) to 30 (high cognitive function).
|
baseline (prior to drug administration) and 60 minutes after drug administration
|
Patient Cognitive Function at 120 Minutes
Time Frame: 120 minutes after drug administration
|
Cognitive function was measured by the Mini-Mental State Examination (MMSE), a brief 30 point questionnaire test.
The scores can range from 0 (low cognitive function) to 30 (high cognitive function).
|
120 minutes after drug administration
|
Blood Pressure at 30 Minutes
Time Frame: 30 minutes after drug administration
|
30 minutes after drug administration
|
|
Heart Rate at 30 Minutes
Time Frame: 30 minutes after drug administration
|
30 minutes after drug administration
|
|
Respiratory Rate at 30 Minutes
Time Frame: 30 minutes after drug administration
|
30 minutes after drug administration
|
|
Pulse Oximetry at 30 Minutes
Time Frame: 30 minutes after drug administration
|
Pulse oximetry measures the oxygenation of a patient's hemoglobin.
A sensor is placed on the patient's finger.
Light at red and infrared wavelengths is passed sequentially through the patient to a photodetector.
The changing absorbance at each of the two wavelengths is measured, allowing determination of the absorbance.
The color of the blood provides a measure of oxygenation (the percentage of hemoglobin molecules bound with oxygen molecules).
A healthy young person will probably have an oxygen saturation of 95-99%.
|
30 minutes after drug administration
|
Blood Pressure at 60 Minutes
Time Frame: 60 minutes after drug administration
|
60 minutes after drug administration
|
|
Heart Rate at 60 Minutes
Time Frame: 60 minutes after drug administration
|
60 minutes after drug administration
|
|
Respiratory Rate at 60 Minutes
Time Frame: 60 minutes after drug administration
|
60 minutes after drug administration
|
|
Pulse Oximetry at 60 Minutes
Time Frame: 60 minutes after drug administration
|
Pulse oximetry measures the oxygenation of a patient's hemoglobin.
A sensor is placed on the patient's finger.
Light at red and infrared wavelengths is passed sequentially through the patient to a photodetector.
The changing absorbance at each of the two wavelengths is measured, allowing determination of the absorbance.
The color of the blood provides a measure of oxygenation (the percentage of hemoglobin molecules bound with oxygen molecules).
A healthy young person will probably have an oxygen saturation of 95-99%.
|
60 minutes after drug administration
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Clark C Otley, MD, Mayo Clinic
- Principal Investigator: Larisa Ravitskiy, MD, Mayo Clinic
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Mental Disorders
- Skin Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Neoplasms, Squamous Cell
- Neoplasms, Basal Cell
- Carcinoma
- Anxiety Disorders
- Carcinoma, Squamous Cell
- Skin Neoplasms
- Carcinoma, Basal Cell
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Anesthetics, Intravenous
- Anesthetics, General
- Anesthetics
- Tranquilizing Agents
- Psychotropic Drugs
- Hypnotics and Sedatives
- Adjuvants, Anesthesia
- Anti-Anxiety Agents
- GABA Modulators
- GABA Agents
- Midazolam
Other Study ID Numbers
- 07-000848
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Anxiety
-
AstraZenecaCompletedAnxiety Disorders | Anxiety | Anxiety Neuroses | Anxiety StatesUnited States
-
Prisma Health-UpstateCompletedAnxiety | Anxiety, Separation | Separation Anxiety | Anxiety Generalized
-
Ann & Robert H Lurie Children's Hospital of ChicagoUniversity of California, Los Angeles; University of CincinnatiRecruitingAnxiety, Separation | Anxiety, Social | Anxiety, GeneralizedUnited States
-
Yale UniversityNational Institute of Mental Health (NIMH)Active, not recruitingGeneralized Anxiety Disorder | Anxiety Disorder of Childhood | Separation Anxiety Disorder of Childhood | Social Anxiety Disorder of ChildhoodUnited States
-
Nazife Begüm KARANCompletedDental Anxiety | Sedative; Anxiety DisorderTurkey
-
Loyola UniversityCompletedAnxiety | Anxiety State | Procedural AnxietyUnited States
-
Eli Lilly and CompanyCompletedAnxiety Neuroses | Anxiety States, Neurotic | Neuroses, AnxietyUnited States, Mexico, South Africa
-
West University of TimisoaraUnknownAnxiety Disorder/Anxiety StateRomania
-
Dr. Nazanin AlaviActive, not recruitingGeneralized Anxiety Disorder | AnxietyCanada
-
ProofPilotFisher WallaceActive, not recruitingGeneralized Anxiety Disorder | Anxiety | Generalized AnxietyUnited States
Clinical Trials on Randomized Midazolam
-
Zhongshan Ophthalmic Center, Sun Yat-sen UniversityCompleted
-
University of California, San FranciscoRecruitingPremature Atrial Contractions | Premature Ventricular ContractionsUnited States
-
Becton, Dickinson and CompanyCompletedCatheter Related ComplicationUnited States
-
Globus Medical IncCompletedLumbar Spinal StenosisUnited States, Puerto Rico
-
Copenhagen Academy for Medical Education and SimulationCompletedClinical CompetenceDenmark
-
Shenzhen Fifth People's HospitalUnknownNK Cell Mediated ImmunityChina
-
Aymara Abreu CorralesUniversity of SalamancaNot yet recruitingMultiple Sclerosis
-
Adiyaman Provincial Health DirectorateCompletedDiabetic Neuropathy, PainfulTurkey
-
Oregon Health and Science UniversityCompletedProstate CancerUnited States
-
Crinetics Pharmaceuticals Inc.Active, not recruitingCarcinoid Tumor | Carcinoid Syndrome | Carcinoid | Carcinoid Tumor of Ileum | Carcinoid Tumor of Cecum | Carcinoid Syndrome Diarrhea | Carcinoid Intestine Tumor | Carcinoid Tumor of Liver | Carcinoid Tumor of PancreasUnited States, Brazil, Argentina, Canada, Mexico, Peru, Poland